D.J. St. Germain’s Neurocrine Biosciences NBIX Stock Holding History

D.J. St. Germain’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$17.9K	Buy	+150	New	+$17.6K	0.01%	241

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.J. St. Germain's NBIX Position: Q4 2022 in Review

D.J. St. Germain opened a new position in Neurocrine Biosciences (NBIX) in Q4 2022: 150 shares worth $17.9K. The stake represents 0.01% of the portfolio and ranks #241 among its holdings.

529 funds tracked by Wall St. Rank hold NBIX as of Q4 2022.

D.J. St. Germain held 150 shares of Neurocrine Biosciences worth $17.9K as of Q4 2022.
Neurocrine Biosciences was a new D.J. St. Germain position in Q4 2022.
Neurocrine Biosciences made up 0.01% of D.J. St. Germain's portfolio in Q4 2022, its #241 holding.
529 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2022.

Based on D.J. St. Germain's 13F filing for Q4 2022, filed 27 Feb 2023.